biostudies-literatureUnknown14(1)Sornsamdang GChulabhorn Royal AcademyBehçet's disease (BD) manifests as an autoimmune disorder featuring recurrent ulcers and multi-organ involvement, influenced by genetic factors associated with both HLA and non-HLA genes, including TNF-α and ERAP1. The study investigated the susceptible alleles of both Class I and II molecules of the HLA gene in 56 Thai BD patients and 192 healthy controls through next-generation sequencing using a PacBio kit. The study assessed 56 BD patients, primarily females (58.9%), revealing diverse manifestations including ocular (41.1%), vascular (35.7%), skin (55.4%), CNS (5.4%), and GI system (10.7%) involvement. This study found associations between BD and HLA-A*26:01:01 (OR 3.285, 95% CI 1.135-9.504, P-value 0.028), HLA-B*39:01:01 (OR 6.176, 95% CI 1.428-26.712, P-value 0.015), HLA-B*51:01:01 (Scientific reports7967https://www.ebi.ac.uk/biostudies/studies/S-EPMC10995258biostudies-literatureNovel genetic variants of HLA gene associated with Thai Behcet's disease (BD) patients using next generation sequencing technology.PMC10995258Limtong PShobana JChanprapaph KSukasem CSornsamdang GChantratita WO-Charoen PChotewutmontri SfalseNovel genetic variants of HLA gene associated with Thai Behcet's disease (BD) patients using next generation sequencing technology.Behçet's disease (BD) manifests as an autoimmune disorder featuring recurrent ulcers and multi-organ involvement, influenced by genetic factors associated with both HLA and non-HLA genes, including TNF-α and ERAP1. The study investigated the susceptible alleles of both Class I and II molecules of the HLA gene in 56 Thai BD patients and 192 healthy controls through next-generation sequencing using a PacBio kit. The study assessed 56 BD patients, primarily females (58.9%), revealing diverse manifestations including ocular (41.1%), vascular (35.7%), skin (55.4%), CNS (5.4%), and GI system (10.7%) involvement. This study found associations between BD and HLA-A*26:01:01 (OR 3.285, 95% CI 1.135-9.504, P-value 0.028), HLA-B*39:01:01 (OR 6.176, 95% CI 1.428-26.712, P-value 0.015), HLA-B*51:01:01 (2024-01-01T00:00:00Z2024 Apr2025-04-18T20:13:33.04Z2025-04-07T08:04:53.656ZS-EPMC109952583857566110.1038/s41598-024-58254-w